Integrated Filing — IndAS



General information about company
Scrip Code 500087
NSE Symbol CIPLA
MSEI Symbol NOTLISTED
ISIN INE059A01026
Name of company CIPLA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 25-Jul-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 01-Jul-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 25-Jul-2025   09:30:00
End date and time of board meeting 25-Jul-2025   13:15:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 69574700000
Other income 2585600000
Total income 72160300000
2 Expenses
(a) Cost of materials consumed 14693500000
(b) Purchases of stock-in-trade 10250200000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -3236600000
(d) Employee benefit expense 13123000000
(e) Finance costs 140500000
(f) Depreciation, depletion and amortisation expense 2527200000
(f) Other Expenses
1 Other Expenses 16963200000 16963200000
Total other expenses 16963200000
Total expenses 54461000000
3 Total profit before exceptional items and tax 17699300000
4 Exceptional items 0
5 Total profit before tax 17699300000
6 Tax expense
7 Current tax 5295500000
8 Deferred tax -516700000
9 Total tax expenses 4778800000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 12920500000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method -4400000
16 Total profit (loss) for period 12916100000
17 Other comprehensive income net of taxes 814100000
18 Total Comprehensive Income for the period 13730200000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 12976200000
Total profit or loss, attributable to non-controlling interests -60100000
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 13788200000
Total comprehensive income for the period attributable to owners of parent non-controlling interests -58000000
21 Details of equity share capital
Paid-up equity share capital 1615500000
Face value of equity share capital 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 16.07
Diluted earnings (loss) per share from continuing operations 16.06
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 16.07
Diluted earnings (loss) per share from continuing and discontinued operations 16.06
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) Since the characters in the notes exceed the set limit, it is requested to refer to the detailed notes in PDF result as uploaded on the Stock Exchanges. n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Pharmaceuticals 65794200000 65794200000
2 New ventures 4437000000 4437000000
Total Segment Revenue 70231200000
Less: Inter segment revenue 656500000 656500000
Revenue from operations 69574700000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Pharmaceuticals 17272200000 17272200000
2 New ventures 567600000 567600000
Total Profit before tax 17839800000
i. Finance cost 140500000 140500000
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax 17699300000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Pharmaceuticals 0 0
2 New ventures 0 0
Total Segment Asset 0 0
Un-allocable Assets 0 0
Net Segment Asset 0 0
4 Segment Liabilities
Segment Liabilities
1 Pharmaceuticals 0 0
2 New ventures 0 0
Total Segment Liabilities 0 0
Un-allocable Liabilities 0 0
Net Segment Liabilities 0 0
Disclosure of notes on segments Textual Information(2)



Text Block
Textual Information(2) Segment assets and liabilities nAs certain assets and liabilities are deployed interchangeably across segments, it is not practically possible to allocate those assets and liabilities to each segment. Hence, the details of assets and liabilities have not been disclosed in the above table. n



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss -85400000 -85400000
Total Amount of items that will not be reclassified to profit and loss -85400000
2 Income tax relating to items that will not be reclassified to profit or loss -21500000
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss 860900000 860900000
Total Amount of items that will be reclassified to profit and loss 860900000
4 Income tax relating to items that will be reclassified to profit or loss -17100000
5 Total Other comprehensive income 814100000